3-Fluoro-5-bromotoluene

We are 3-Fluoro-5-bromotoluene CAS:202865-83-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Name: 3-Fluoro-5-bromotoluene
Other Name: 1-Bromo-3-fluoro-5-methylbenzene;5-Bromo-3-fluorotoluene
CAS No: 202865-83-6
MF: C7H6BrF
MW: 189.02500
Density: 1.498g/cm3
Boiling point: 183.4ºC at 760 mmHg
Flash point: 67.1ºC
Refractive index: 1.526
Vapor Pressure: 1.05mmHg at 25°C
UN Number: UN1993
UN Proper Shipping Name: FLAMMABLE LIQUID, N.O.S.
Transport hazard class: N.A
Packing group: N.A
 
Specification
Appearance: Colorless to light yellow transparent liquid
Purity: ≥98%
Water: ≤0.5%
 
Application: Organic intermediates, pharmaceutical intermediates.
Package: 25kg/drum, packed in plastic drum or plastic coated iron drum.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

3-Fluoro-5-bromotoluene


Related News: Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.2-bromo-4-chloropyridine This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?9'-phenyl-9H,9'H-2,3'-bicarbazole CAS:1345202-03-0 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?N- (2-cloroetil) carbamato de etilo CAS:6329-26-6 The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term.The overall competition in China’s specialty drug substance market is relatively moderate, but due to the higher technical barriers and higher entry barriers for new entrants, there will be no obvious intensified competition in the short term.

Related Products
Product Name
2-(Trifluoromethoxy)benzonitrile View Details
boc-l-tyr-ol View Details
4-Tert-Butylbenzenesulfonamide View Details
5-fluoroanthranilic acid manufacturer 3,5-Dichloropyridine-2-carbonitrile manufacturer (1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethanol manufacturer 4-chloro-2-methylbenzoic acid manufacturer 1,6-DIIODOHEXANE manufacturer